Mahmoud Teaima1, Rehab Abdelmonem2, Yomna A Adel3, Mohamed A El-Nabarawi1, Tayseer M El-Nawawy3. 1. Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt. 2. Department of Industrial Pharmacy, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology (MUST), 6th of October City, Giza, 12566, Egypt. 3. Department of Pharmaceutics, Egyptian Drug Authority, Cairo, Egypt.
Abstract
PURPOSE: The purpose of this study was to prepare telmisartan transethosomes, incorporate them into a gel, evaluate them for in vitro drug release and in vivo permeation using iontophoresis to enhance their transdermal delivery. MATERIALS AND METHODS: TE formulae were prepared using various surfactants (SAAs), different ethanol concentrations, and different phospholipid-to-SAA ratios with different cholesterol ratios, characterized according to their entrapment efficiency percentage (EE%), zeta potential (ZP), particle size (PS), and polydispersity index (PDI). The optimum three formulae were incorporated into a gel, evaluated physically, in vitro dissolution, and ex vivo drug permeation using rat skin and Iontophoresis was performed on the best formula. RESULTS: The optimum three formulae (F29, F31, F32) had an EE% of 97±0.26%, 89±0.25% and 88±0.17%, PS of 244±5.88 nm, 337±4.6 nm and 382.2±3.06 nm, PDI of 0.57±1.9, 0.5±1.4 and 0.63±2.2 and ZP of -31.6±1.59 mV, -28.3±3.79 mV and -31±5.65, respectively. Selecting F29 for in vivo study by iontophoretic enhancement, Cmax was increased by 1.85 folds compared to the commercial oral tablet and by 1.5 folds compared to transdermal gel. Tmax decreased by half using iontophoresis compared to commercial tablets and transdermal gel. CONCLUSION: The transethosomal formulation of telmisartan enhanced its transdermal absorption and increased its bioavailability as well. Iontophoresis was used to increase maximum plasma concentration and reduce Tmax by half.
PURPOSE: The purpose of this study was to prepare telmisartan transethosomes, incorporate them into a gel, evaluate them for in vitro drug release and in vivo permeation using iontophoresis to enhance their transdermal delivery. MATERIALS AND METHODS: TE formulae were prepared using various surfactants (SAAs), different ethanol concentrations, and different phospholipid-to-SAA ratios with different cholesterol ratios, characterized according to their entrapment efficiency percentage (EE%), zeta potential (ZP), particle size (PS), and polydispersity index (PDI). The optimum three formulae were incorporated into a gel, evaluated physically, in vitro dissolution, and ex vivo drug permeation using rat skin and Iontophoresis was performed on the best formula. RESULTS: The optimum three formulae (F29, F31, F32) had an EE% of 97±0.26%, 89±0.25% and 88±0.17%, PS of 244±5.88 nm, 337±4.6 nm and 382.2±3.06 nm, PDI of 0.57±1.9, 0.5±1.4 and 0.63±2.2 and ZP of -31.6±1.59 mV, -28.3±3.79 mV and -31±5.65, respectively. Selecting F29 for in vivo study by iontophoretic enhancement, Cmax was increased by 1.85 folds compared to the commercial oral tablet and by 1.5 folds compared to transdermal gel. Tmax decreased by half using iontophoresis compared to commercial tablets and transdermal gel. CONCLUSION: The transethosomal formulation of telmisartan enhanced its transdermal absorption and increased its bioavailability as well. Iontophoresis was used to increase maximum plasma concentration and reduce Tmax by half.
Authors: Magdy I Mohammed; Amna M A Makky; Mahmoud H M Teaima; Menna M Abdellatif; Mohamed A Hamzawy; Mahmoud A F Khalil Journal: Drug Deliv Date: 2015-03-02 Impact factor: 6.419
Authors: Mahmoud H Teaima; Sally A Abdelhalim; Mohamed A El-Nabarawi; Dalia A Attia; Doaa A Helal Journal: Drug Dev Ind Pharm Date: 2017-10-17 Impact factor: 3.225
Authors: Ahmed H H Bakheit; Ahmed A Abd-Elgalil; Bakheit Mustafa; Anzarul Haque; Tanveer A Wani Journal: Profiles Drug Subst Excip Relat Methodol Date: 2015-03-31
Authors: Ana C Mendes; Christian Gorzelanny; Natalia Halter; Stefan W Schneider; Ioannis S Chronakis Journal: Int J Pharm Date: 2016-06-07 Impact factor: 5.875